GIBSON DUNN

Gibson Dunn Advises Coastlands Capital on up to $40 Million Financing for AN2 Therapeutics, Inc.

Firm News | March 9, 2026

Gibson Dunn represented Coastlands Capital as lead investor in the up to $40 million private placement financing for AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform.

Gibson Dunn regularly advises life sciences investors on private placement financings for clinical-stage biopharmaceutical companies.

The Gibson Dunn team included Ryan Murr and Branden Berns.

Related Capabilities

Life Sciences

Finance

Private Equity

Emerging Companies / Venture Capital

Related People

Ryan A. Murr

Branden C. Berns

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**